Invasive recurrence after breast conserving treatment of ductal carcinoma in situ of the breast in the Netherlands: time trends and the association with tumour grade.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
    • Publication Information:
      Publication: 2002- : London : Nature Publishing Group on behalf of Cancer Research UK
      Original Publication: London, Lewis.
    • Subject Terms:
      Mastectomy, Segmental* ; Carcinoma, Intraductal, Noninfiltrating*/pathology ; Carcinoma, Intraductal, Noninfiltrating*/radiotherapy ; Carcinoma, Intraductal, Noninfiltrating*/surgery ; Carcinoma, Intraductal, Noninfiltrating*/epidemiology ; Carcinoma, Intraductal, Noninfiltrating*/therapy ; Breast Neoplasms*/pathology ; Breast Neoplasms*/surgery ; Breast Neoplasms*/epidemiology ; Breast Neoplasms*/radiotherapy ; Breast Neoplasms*/therapy ; Neoplasm Recurrence, Local*/epidemiology ; Neoplasm Recurrence, Local*/pathology ; Neoplasm Grading*; Humans ; Female ; Netherlands/epidemiology ; Middle Aged ; Retrospective Studies ; Aged ; Adult ; Radiotherapy, Adjuvant/statistics & numerical data ; Registries ; Aged, 80 and over
    • Abstract:
      Background: The first aim of this study was to examine trends in the risk of ipsilateral invasive breast cancer (iIBC) after breast-conserving surgery (BCS) of ductal carcinoma in situ (DCIS). A second aim was to analyse the association between DCIS grade and the risk of iIBC following BCS.
      Patients and Methods: In this population-based, retrospective cohort study, the Netherlands Cancer Registry collected information on 25,719 women with DCIS diagnosed in the period 1989-2021 who underwent BCS. Of these 19,034 received adjuvant radiotherapy (RT). Kaplan-Meier analyses and Cox regression models were used.
      Results: A total of 1135 patients experienced iIBC. Ten-year cumulative incidence rates of iIBC for patients diagnosed in the periods 1989-1998, 1999-2008 and 2009-2021 undergoing BCS without RT, were 12.6%, 9.0% and 5.0% (P < 0.001), respectively. For those undergoing BCS with RT these figures were 5.7%, 3.7% and 2.2%, respectively (P < 0.001). In the multivariable analyses, DCIS grade was not associated with the risk of iIBC.
      Conclusion: Since 1989 the risk of iIBC has decreased substantially and has become even lower than the risk of invasive contralateral breast cancer. No significant association of DCIS grade with iIBC was found, stressing the need for more powerful prognostic factors to guide the treatment of DCIS.
      (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
    • References:
      Eur J Cancer. 2015 Nov;51(16):2296-303. (PMID: 26296293)
      Br J Surg. 2019 Oct;106(11):1488-1494. (PMID: 31386197)
      Lancet. 2020 May 23;395(10237):1613-1626. (PMID: 32580883)
      J Natl Cancer Inst Monogr. 2010;2010(41):162-77. (PMID: 20956824)
      Br J Cancer. 2019 Aug;121(4):285-292. (PMID: 31285590)
      J Natl Cancer Inst. 2002 Oct 16;94(20):1546-54. (PMID: 12381707)
      Eur J Cancer. 2015 Aug;51(12):1497-510. (PMID: 26025767)
      Clin Breast Cancer. 2019 Feb;19(1):35-46. (PMID: 30190195)
      Breast Cancer Res Treat. 2021 May;187(1):245-254. (PMID: 33385265)
      Br J Cancer. 2021 Mar;124(5):1009-1017. (PMID: 33199800)
      Breast Cancer Res Treat. 2019 Apr;174(2):479-488. (PMID: 30539380)
      Ann Oncol. 2019 Aug 1;30(8):1194-1220. (PMID: 31161190)
      J Natl Cancer Inst. 2011 Mar 16;103(6):478-88. (PMID: 21398619)
      Eur J Cancer. 2018 Sep;101:210-219. (PMID: 30092498)
      Breast. 2017 Feb;31:274-283. (PMID: 27671693)
      Lab Invest. 2021 Apr;101(4):525-533. (PMID: 33608619)
      J Pathol Clin Res. 2021 May;7(3):233-242. (PMID: 33620141)
      Lancet. 2022 Aug 6;400(10350):431-440. (PMID: 35934006)
      Breast Cancer Res Treat. 2013 Jun;139(2):453-60. (PMID: 23624751)
      N Engl J Med. 2012 Nov 22;367(21):1998-2005. (PMID: 23171096)
      Ann Clin Lab Sci. 2006 Winter;36(1):16-22. (PMID: 16501232)
      J Digit Imaging. 2018 Aug;31(4):387-392. (PMID: 28932980)
      Curr Oncol. 2018 Apr;25(2):133-138. (PMID: 29719429)
      BMJ. 2023 Oct 30;383:e076022. (PMID: 37903527)
      Breast Cancer Res Treat. 2016 Oct;159(3):553-63. (PMID: 27624164)
      Breast Cancer Res Treat. 2013 Apr;138(2):581-90. (PMID: 23456231)
      BMJ Open. 2019 Mar 12;9(3):e026797. (PMID: 30862637)
      Ann Surg Oncol. 2017 Oct;24(10):2889-2897. (PMID: 28766208)
      N Engl J Med. 2010 Feb 11;362(6):513-20. (PMID: 20147717)
      Am J Surg Pathol. 1998 Feb;22(2):256-9. (PMID: 9500229)
      J Clin Oncol. 2023 Jun 10;41(17):3092-3099. (PMID: 37126767)
      Lancet Oncol. 2013 Oct;14(11):1086-1094. (PMID: 24055415)
      Mod Pathol. 2002 Feb;15(2):95-101. (PMID: 11850537)
      J Cancer Epidemiol. 2017;2017:6091709. (PMID: 29056966)
      J Clin Oncol. 2023 Jun 10;41(17):3116-3121. (PMID: 36917758)
      J Natl Cancer Inst. 2019 Sep 1;111(9):952-960. (PMID: 30759222)
      Clin Cancer Res. 2020 Aug 1;26(15):4054-4063. (PMID: 32341032)
      Pract Radiat Oncol. 2017 Mar - Apr;7(2):73-79. (PMID: 27866865)
      J Clin Oncol. 2013 Nov 10;31(32):4054-9. (PMID: 24043739)
      Breast. 2022 Feb;61:145-155. (PMID: 34999428)
    • Publication Date:
      Date Created: 20240709 Date Completed: 20240902 Latest Revision: 20240905
    • Publication Date:
      20240905
    • Accession Number:
      PMC11369187
    • Accession Number:
      10.1038/s41416-024-02785-6
    • Accession Number:
      38982194